Approach to the Diagnosis of Invasive Aspergillosis and Candidiasis

Clinics in Chest Medicine

Volumn 30, Issue 2, 2009, Pages 367-377

  Wheat, L Joseph ^a  

^a MIRAVISTA DIAGNOSTICS   (United States)

Author keywords

Antigen detection; Aspergillosis; Candidiasis; Diagnosis; Mucormycosis; Mycosis; Serology; Zygomycosis

Indexed keywords

(1 3) BETA D GLUCAN; ANTIGEN; GLUCAN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ASPERGILLOSIS; CANDIDIASIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; INFECTION RISK; INVASIVE CANDIDIASIS; LUNG LAVAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROLOGY;

ASPERGILLOSIS; CANDIDIASIS; GLUCANS; HUMANS; MONITORING, PHYSIOLOGIC;

EID: 64249148773     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2009.02.012     Document Type: Review

References (69)

1. Meersseman W., Lagrou K., Maertens J., et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 45 2 (2007) 205-216
2. Maschmeyer G., Haas A., and Cornely O.A. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67 11 (2007) 1567-1601
3. Maertens J., Theunissen K., Lodewyck T., et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 50 Suppl 1 (2007) 2-17
4. Wheat L.J., and Walsh T.J. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis 27 4 (2008) 245-251
5. Mennink-Kersten M.A., Donnelly J.P., and Verweij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4 6 (2004) 349-357
6. Maertens J., Van Eldere J., Verhaegen J., et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 186 9 (2002) 1297-1306
7. Maertens J., Verhaegen J., Demuynck H., et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 37 10 (1999) 3223-3228
8. Meersseman W., Lagrou K., Maertens J., et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177 1 (2008) 27-34
9. Pfeiffer C.D., Fine J.P., and Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42 10 (2006) 1417-1427
10. Wheat L. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 5 4 (2003) 158-166
11. Maertens J., Theunissen K., Verbeken E., et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126 6 (2004) 852-860
12. Maertens J.A., Klont R., Masson C., et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 44 10 (2007) 1329-1336
13. Marr K.A., Balajee S.A., McLaughlin L., et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190 3 (2004) 641-649
14. Busca A., Locatelli F., Barbui A., et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 38 5 (2006) 1610-1613
15. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 9 (2005) 1242-1250
16. Sulahian A., Touratier S., and Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 349 24 (2003) 2366-2367
17. Walsh T.J., Shoham S., Petraitiene R., et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 42 10 (2004) 4744-4748
18. Racil Z., Kocmanova I., Lengerova M., et al. Intravenous PLASMA-LYTE as a major cause of false-positive results of Platelia Aspergillus test for galactomannan detection in serum. J Clin Microbiol 45 9 (2007) 3141-3142
19. Hage C.A., Reynolds J.M., Durkin M., et al. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol 45 2 (2007) 676-677
20. Stynen D., Sarfati J., Goris A., et al. Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun 60 6 (1992) 2237-2245
21. Swanink C.M.A., Meis J.F.G.M., Rijs A.J.M.M., et al. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 35 1 (1997) 257-260
22. Giacchino M., Chiapello N., Bezzio S., et al. Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J Clin Microbiol 44 9 (2006) 3432-3434
23. Huang Y.T., Hung C.C., Liao C.H., et al. Detection of circulating galactomannan in Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol 45 (2007) 2858-2862
24. Wheat L.J., Hackett E., Durkin M., et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol 14 5 (2007) 638-640
25. Cummings J.R., Jamison G.R., Boudreaux J.W., et al. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis 59 1 (2007) 113-115
26. Dalle F., Charles P.E., Blanc K., et al. Cryptococcus neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 43 6 (2005) 2929-2931
27. De Jesus M., Hackett E., Durkin M., et al. Galactoxylomannan does not exhibit cross-reactivity in the Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol 14 5 (2007) 624-627
28. Asano-Mori Y., Kanda Y., Oshima K., et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 61 2 (2008) 411-416
29. Hayden R., Pounds S., Knapp K., et al. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J 27 9 (2008) 815-819
30. Marr K.A., Laverdiere M., Gugel A., et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40 12 (2005) 1762-1769
31. Becker M.J., Lugtenburg E.J., Cornelissen J.J., et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 121 3 (2003) 448-457
32. Musher B., Fredricks D., Leisenring W., et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 42 12 (2004) 5517-5522
33. Husain S., Paterson D.L., Studer S.M., et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 83 10 (2007) 1330-1336
34. Clancy C.J., Jaber R.A., Leather H.L., et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 45 6 (2007) 1759-1765
35. Husain S., Clancy C.J., Nguyen M.H., et al. Performance characteristics of the platelia aspergillus enzyme immunoassay for detection of aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 15 12 (2008) 1760-1763
36. Nguyen M.H., Jaber R., Leather H.L., et al. Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol 45 9 (2007) 2787-2792
37. Husain S., Paterson D.L., Studer S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 12 (2006) 3008-3016
38. Lass-Florl C., Resch G., Nachbaur D., et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 45 7 (2007) e101-e104
39. Klont R.R., Mennink-Kersten M.A., and Verweij P.E. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 39 10 (2004) 1467-1474
40. Rohrlich P., Sarfati J., Mariani P., et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J 15 2 (1996) 232-237
41. Bretagne S., Marmorat-Khuong A., Kuentz M., et al. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect 35 1 (1997) 7-15
42. Maertens J., Verhaegen J., Lagrou K., et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97 6 (2001) 1604-1610
43. Boutboul F., Alberti C., Leblanc T., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 34 7 (2002) 939-943
44. Miceli M.H., Grazziutti M.L., Woods G., et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 46 9 (2008) 1412-1422
45. Miceli M.H., Maertens J., Buve K., et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 110 1 (2007) 112-120
46. Obayashi T., Yoshida M., Mori T., et al. Plasma (1->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345 8941 (1995) 17-20
47. Senn L., Robinson J.O., Schmidt S., et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46 6 (2008) 878-885
48. Kawazu M., Kanda Y., Nannya Y., et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1->3)-{beta}-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 42 6 (2004) 2733-2741
49. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-D-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39 2 (2004) 199-205
50. Pazos C., Ponton J., and Palacio A.D. Contribution of (1->3)-{beta}-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43 1 (2005) 299-305
51. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24 10 (2005) 654-661
52. Akamatsu N., Sugawara Y., Kaneko J., et al. Preemptive treatment of fungal infection based on plasma (1 -> 3)beta-D: -glucan levels after liver transplantation. Infection 35 5 (2007) 346-351
53. Persat F., Ranque S., Derouin F., et al. Contribution of the (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 46 3 (2008) 1009-1013
54. Digby J., Kalbfleisch J., Glenn A., et al. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10 5 (2003) 882-885
55. Pickering J.W., Sant H.W., Bowles C.A.P., et al. Evaluation of a (1->3)-{beta}-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 43 12 (2005) 5957-5962
56. Ellis M., Al Ramadi B., Finkelman M., et al. Assessment of the clinical utility of serial {beta}-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57 Pt 3 (2008) 287-295
57. Egan L., Connolly P., Wheat L.J., et al. Histoplasmosis as a cause for a positive Fungitell (1->3)-beta-D-glucan test. Med Mycol 46 1 (2008) 93-95
58. Tasaka S., Hasegawa N., Kobayashi S., et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 131 4 (2007) 1173-1180
59. Smith P.B., Benjamin Jr. D.K., Alexander B.D., et al. Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol 14 7 (2007) 924-925
60. Stevens D.A., Moss R.B., Kurup V.P., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 37 (2003) S225-S264
61. Soubani A.O., and Chandrasekar P.H. The clinical spectrum of pulmonary aspergillosis. Chest 121 6 (2002) 1988-1999
62. Cruciani M., and Serpelloni G. Management of Candida infections in the adult intensive care unit. Expert Opin Pharmacother 9 2 (2008) 175-191
63. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents Chemother 49 9 (2005) 3640-3645
64. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 1 (2006) 25-31
65. Mitsutake K., Miyazaki T., Tashiro T., et al. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia. J Clin Microbiol 34 8 (1996) 1918-1921
66. Mohr JF, Paetznick V, Rodriguez J, et al. A Prospective pilot survey of B-glucan seropositivity and its relationship to invasive candidiasis in the surgical ICU [Abstract M-168]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, 2005.
67. Alam F.F., Mustafa A.S., and Khan Z.U. Comparative evaluation of (1,3)-beta-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis 7 1 (2007) 103
68. Rimek D., Redetzke K., Steiner B., et al. [Experience with the Platelia Candida ELISA for the diagnostics of invasive candidosis in neutropenic patients]. Mycoses 47 Suppl 1 (2004) 27-31 [in German]
69. Sharafkhaneh A., Baaklini W., Gorin A.B., et al. Yield of transbronchial needle aspiration in diagnosis of mediastinal lesions. Chest 124 6 (2003) 2131-2135